B. Riley Cuts CryoPort (NASDAQ:CYRX) Price Target to $24.00

CryoPort (NASDAQ:CYRX) had its price objective lowered by B. Riley from $26.00 to $24.00 in a research report released on Thursday, BenzingaRatingsTable reports. The brokerage currently has a buy rating on the consumer goods maker’s stock.

CYRX has been the topic of a number of other research reports. Needham & Company LLC lowered their price objective on CryoPort from $24.00 to $22.00 and set a buy rating on the stock in a report on Monday, January 13th. Stephens began coverage on CryoPort in a report on Tuesday, January 7th. They set an overweight rating and a $21.00 price objective on the stock. BidaskClub lowered CryoPort from a sell rating to a strong sell rating in a report on Friday, January 31st. Finally, ValuEngine lowered CryoPort from a buy rating to a hold rating in a report on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $22.75.

Shares of NASDAQ CYRX traded down $0.46 during mid-day trading on Thursday, reaching $18.67. 255,510 shares of the company traded hands, compared to its average volume of 446,652. The company has a debt-to-equity ratio of 0.17, a quick ratio of 17.84 and a current ratio of 17.91. The stock has a market cap of $672.00 million, a PE ratio of -31.64 and a beta of 0.79. The company’s fifty day moving average is $18.15 and its two-hundred day moving average is $17.46. CryoPort has a fifty-two week low of $9.85 and a fifty-two week high of $25.02.

In related news, Director Richard J. Berman sold 5,000 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $14.66, for a total transaction of $73,300.00. Also, CFO Robert Stefanovich sold 135,036 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $14.80, for a total value of $1,998,532.80. 11.00% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in CYRX. Bank of America Corp DE boosted its position in shares of CryoPort by 45.6% in the 4th quarter. Bank of America Corp DE now owns 28,490 shares of the consumer goods maker’s stock worth $469,000 after purchasing an additional 8,928 shares during the last quarter. UBS Asset Management Americas Inc. bought a new position in CryoPort during the fourth quarter worth about $253,000. Fred Alger Management LLC lifted its holdings in CryoPort by 1.8% during the fourth quarter. Fred Alger Management LLC now owns 4,664,578 shares of the consumer goods maker’s stock worth $76,779,000 after acquiring an additional 82,380 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in CryoPort by 59.6% during the fourth quarter. Goldman Sachs Group Inc. now owns 94,024 shares of the consumer goods maker’s stock worth $1,547,000 after acquiring an additional 35,106 shares in the last quarter. Finally, UBS Group AG lifted its holdings in CryoPort by 84.4% during the fourth quarter. UBS Group AG now owns 43,734 shares of the consumer goods maker’s stock worth $720,000 after acquiring an additional 20,021 shares in the last quarter. Hedge funds and other institutional investors own 73.84% of the company’s stock.

CryoPort Company Profile

CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.

Recommended Story: Compound Annual Growth Rate (CAGR)

Analyst Recommendations for CryoPort (NASDAQ:CYRX)

Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.